ISRG - Intuitive Surgical, Inc.
| Previous Close | 556.7700 |
| Open | 556.3600 |
| Bid | 568.5600 x 1800 |
| Ask | 568.8500 x 800 |
| Day's Range | 553.0770 - 568.7850 |
| 52 Week Range | 337.7967 - 572.9600 |
| Volume | 263,383 |
| Avg. Volume | 640,864 |
| Market Cap | 64.69B |
| Beta | 1.11 |
| PE Ratio (TTM) | 83.87 |
| EPS (TTM) | 6.7810 |
| Earnings Date | Oct 17, 2018 - Oct 22, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 569.80 |
- Zacks•5 hours ago
Intuitive Surgical and InTouch Collaborate for IoMT Services
Intuitive Surgical's (ISRG) IoMT likely to benefit patients; market prospects impressive.
- Motley Fool•yesterday
Better Buy: Intuitive Surgical, Inc. vs. Medtronic plc
The robotic surgery kingpin versus a medical device titan: Which one is the better bet for new money today?
Motley Fool•3 days agoIs Medtronic Paying Too Much for Mazor Robotics?
This medical-device titan is paying up to swallow the robotic-surgery upstart whole. Does the deal make sense?
- Zacks•3 days ago
Here's Why You Should Buy Intuitive Surgical (ISRG) Now
Strength in the surgical platform and a string of developments make Intuitive Surgical (ISRG) a promising pick.
- Zacks•3 days ago
Medtronic to Buy Mazor Robotics for Robotic Spine Surgery
The consolidation will combine Medtronic's (MDT) spine implants, navigation and intra-operative imaging technology with Mazor Robotics' robotic-assisted surgery (RAS) systems.
- Zacks•3 days ago
3 MedTech Stocks for Safe Returns as Hurricane Fears Peak
With the hurricane season at the peak, we bring three safe picks for investors.
- Zacks•3 days ago
Cerner's CommunityWorks Picked by Reeves County Hospital
Cerner (CERN) sees a slew of developments in its EHR platform, market prospects bright.
- Zacks•3 days ago
Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now
Becton, Dickinson (BD) is likely to gain from expansion into emerging overseas markets.
- PR Newswire•4 days ago
InTouch Health to Build an Internet of Medical Things Network for Intuitive
SANTA BARBARA, Calif., Sept. 20, 2018 /PRNewswire/ -- InTouch Health, the leading enterprise telehealth platform, today announced it has signed a multi-year licensing service agreement with Intuitive Surgical, Inc. (ISRG), the pioneer and a global technology leader in robotic-assisted, minimally invasive surgery. Under the agreement, the two companies will collaborate to deepen Intuitive's Internet of Medical Things (IoMT) network to connect into thousands of da Vinci surgical systems in medical institutions around the world on a single global network. InTouch Health's proprietary IoMT network will enable healthcare companies like Intuitive, to connect directly to their surgical systems worldwide to exchange real-time data for enhanced clinical insights, proactive service and maintenance monitoring, surgical collaboration between disparate locations, and the ability to extract data for data analytics and machine learning.
Market Realist•4 days agoWhat Quest Diagnostics’ Valuation Trend Indicates
In September 2018, of the total 18 analysts covering Quest Diagnostics (DGX), ten analysts have given Quest stock a “buy” or higher rating, and eight analysts have given Quest a “hold” rating. The mean rating for Quest stock is 2.22 with a target price of $116.86 implying an upside potential of 9% over Quest’s closing price of $107.22 on September 18, 2018.
Market Realist•5 days agoHow Quest Diagnostics Is Positioned in 2018
Quest Diagnostics (DGX) is a leading provider of diagnostic information services. Quest makes use of its database of clinical lab results to gain diagnostic insights that help to improve healthcare management. Quest’s diagnostics information services business (or DIS) provides data and insights based on routine, non-routine, and advanced clinical testing, as well as anatomic pathology testing and other diagnostic information services.
Market Realist•5 days agoWhat’s the Upside Potential of Thermo Fisher Scientific Stock?
So far in 2018, Thermo Fisher Scientific (TMO) stock has generated double-digit returns for investors. Boosted by its strong financial performance, it’s risen from $192.98 on January 2 to its current level of $240 in September.
Market Realist•5 days agoWhat Thermo Fisher Scientific’s Gross Margin Trend Indicates
Thermo Fisher Scientific (TMO) is a leading provider of analytical instruments, equipment, reagents, and consumables. Thermo Fisher Scientific generated total revenue of $6.08 billion in the second quarter compared to $4.99 billion in the comparable period of 2017. Thermo Fisher generates revenue from product sales and services.
- MarketWatch•5 days ago
7 ways to invest in the automation megatrend
To hear some politicians tell it, unfair trade and labor practices have been killing American factory jobs and punishing the U.S. economy for years — and 2018 is finally the year we fight back. As Michael Hicks and Srikant Devaraj of Ball State noted in a research report entitled “The Myth and Reality of Manufacturing in America,” productivity in the sector has exploded in the last decade or two thanks to technological innovations, with automation chief among them. For example, if productivity had remained constant from the year 2000 to 2010, U.S. manufacturers would have employed 20.9 million workers in 2010 to achieve that year’s total output, rather than just 12.1 million.
- Zacks•5 days ago
Here's Why You Should Hold AngioDynamics' (ANGO) Stock Now
AngioDynamics (ANGO) to benefit from a solid product portfolio. However, the company???s core Peripheral Vascular business has been sluggish.
- Zacks•5 days ago
Veeva's Vault CDMS to Unify Clinical Data in Single Platform
Veeva's (VEEV) cloud-based applications' market prospects bright.
- Zacks•6 days ago
ResMed Unveils AirFit F30, Expands AirFit Mask Portfolio
ResMed's (RMD) recent product launches will strengthen its position in the high-potential sleep-disordered breathing market.
- Zacks•6 days ago
QIAGEN (QGEN) Partners DiaSorin to Extend QuantFERON Offers
Per QIAGEN (QGEN), the latest LIAISON QuantiFERON-TB Plus Test is likely to tackle the growing transformation of global latent TB testing market into the modern blood-based QuantiFERON technology.
- Zacks•6 days ago
Cooper's MiSight Lens Effective in Checking Juvenile Myopia
Cooper's (COO) core CVI business gets a boost from MiSight's positive study results.
- Zacks•6 days ago
Can Intuitive Surgical (ISRG) Keep the Earnings Surprise Streak Alive?
Intuitive Surgical (ISRG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks•6 days ago
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
Abbott (ABT) continues to deliver strong and consistent performance in all segments. The company has also been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre.
- Zacks•7 days ago
CVS Health (CVS) PBM Strengthens, Aetna Deal Shows Promise
A robust 2019 PBM selling season is a tailwind for CVS Health (CVS). Additionally, the company's milestone acquisition of Aetna might alter the whole healthcare landscape in the United States.
- Zacks•7 days ago
QIAGEN Collaborates With NeuMoDx, Expands NGS Portfolio
QIAGEN (QGEN) forges ahead with deals to strengthen the NGS Platform.
- Zacks•7 days ago
DaVita Kidney Care Opens 150000-Square-Foot Campus in DeLand
DaVita's (DVA) dialysis care in the United States gets a boost; market prospects solid.
- Zacks•10 days ago
Pacific Biosciences (PACB) Up as VGP Picks Flagship Sequel
Pacific Biosciences (PACB) sees a slew of developments in its coveted SMRT Sequel platform.
